The Sahajanand Medical Technologies IPO is a book-built issue worth ₹475.48 crore, made up entirely of an offer for sale of 1.38 crore shares.
The Sahajanand Medical Technologies IPO opened for bidding on Oct 15, 2026 and closes on Oct 19, 2026. Allotment is expected to be finalized on Oct 21, and the shares will list on the NSE and BSE on Oct 23, 2026 (tentative).
The Sahajanand Medical Technologies IPO has a price band of ₹327 to ₹344 per share, with a lot size of 43 shares. At the upper price band, retail investors need a minimum of ₹14,792 (1 lot, 43 shares).
For the Sahajanand Medical Technologies IPO, MUFG Intime India Pvt. Ltd. is the registrar of the issue.
Investors can refer to the Sahajanand Medical Technologies IPO RHP for detailed information.
| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 43 | 14,792 |
| HNI / NII | 68 | 2924 | 10,05,856 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 1.59× | 27,14,424 | 43,21,973 | ₹148.68 Cr |
| NII / HNI (Total) | 3.69× | 20,35,817 | 75,13,863 | ₹258.48 Cr |
| Retail Investors | 1.65× | 47,50,241 | 78,29,010 | ₹269.32 Cr |
| Employee Shares Offered | — | 2,50,000 | — | — |
| Market Maker * | 1× | — | — | — |
| Total ** | 2.02× | 97,50,482 | 1,97,27,024 | ₹678.61 Cr |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 1.12× | 27,14,424 | 30,48,700 | ₹104.88 Cr |
| NII / HNI (Total) | 0.51× | 20,35,817 | 10,37,977 | ₹35.71 Cr |
| Retail Investors | 0.83× | 47,50,241 | 39,41,294 | ₹135.58 Cr |
| Market Maker * | 1× | — | — | — |
| Total ** | 0.83× | 97,50,482 | 80,62,242 | ₹277.34 Cr |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 1.59× | 27,14,424 | 43,21,973 | ₹148.68 Cr |
| NII / HNI (Total) | 3.69× | 20,35,817 | 75,13,863 | ₹258.48 Cr |
| Retail Investors | 1.65× | 47,50,241 | 78,29,010 | ₹269.32 Cr |
| Market Maker * | 1× | — | — | — |
| Total ** | 2.02× | 97,50,482 | 1,97,27,024 | ₹678.61 Cr |
| Metric | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 |
|---|---|---|---|
| Revenue | 354.33 | 1218.73 | 1035.96 |
| PAT | 15.09 | 69.08 | 25.15 |
| EBITDA | 48.58 | 170.66 | 128.02 |
| Net Worth | 631.72 | 616.05 | 545.23 |
| Total Assets | 1309.00 | 1276.43 | 1094.90 |
| Reserves | 706.86 | 692.48 | 580.71 |
| Borrowings | 320.63 | 269.53 | 224.96 |
Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). The Company focuses on research and development, precision manufacturing and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.
The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India. Its products were marketed in 77 countries in Fiscal 2026, through direct, hybrid and distributor-led models, with established market presence in India, Europe and other international markets.
The Company reported revenue from operations of ₹12,105.04 million in Fiscal 2026, compared with ₹10,248.79 million in Fiscal 2025 and ₹9,016.04 million in Fiscal 2024.
As of June 30, 2026, it had 1,605 full-time employees, 31 consultants and 707 contract-based employees.
Competitive Strengths
Sahajanand Medical Technologies Ltd IPO · Expected 21 Oct 2026
Check on Registrar